EUVIMEDEUVIMED entdecken
Crossref

Topical delivery of mitogen-activated protein kinase inhibitor binimetinib prevents the development of cutaneous neurofibromas in neurofibromatosis type 1 mutant mice

Fanny Coulpier, Pernelle Pulh, Layna Oubrou, Julie Naudet, Laura Fertitta, Jean-Marc Gregoire, Arnaud Bocquet, Anne-Marie Schmitt, Pierre Wolkenstein, Katarzyna J Radomska, Piotr Topilko

Translational Research · 2023

DOI: 10.1016/j.trsl.2023.06.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Research, 2023. Verfasst von Fanny Coulpier und 10 weiteren Autor:innen. Beteiligte Einrichtung: Mondor Institute for Biomedical Research, Creteil, France. Hauptthemen laut MEDLINE: Neurofibromatosis 1, Neurofibroma, Skin Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Johns Hopkins University, Les Laboratories Pierre Fabre, Neurofibromatosis Therapy Acceleration Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cutaneous neurofibromas (cNFs) are a hallmark of patients with the neurofibromatosis type 1 (NF1) genetic disorder. These benign nerve sheath tumors, which can amount to thousands, develop from puberty onward, often cause pain and are considered by patients to be the primary burden of the disease. Mutations of NF1, encoding a negative regulator of the RAS signaling pathway, in the Schwann cell (SCs) lineage are considered to be at the origin of cNFs. The mechanisms governing cNFs development are poorly understood, and therapeutics to reduce cNFs are missing, mainly due to the lack of appropriate animal models. To address this, we designed the Nf1-KO mouse model that develops cNFs. Using this model, we found that cNFs development is a singular event and goes through 3 successive stages: initiation, progression, and stabilization characterized by changes in the proliferative and MAPK activities of tumor SCs. We found that skin trauma accelerated the development of cNFs and further used this model to explore the efficacy of the MEK inhibitor binimetinib to cure these tumors. We showed that while topically delivered binimetinib has a selective and minor effect on mature cNFs, the same drug prevents their development over long periods.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neurofibromatosis 1NeurofibromaSkin NeoplasmsHumansMiceAnimalsBenzimidazolesProtein Kinase InhibitorsMitogen-Activated Protein Kinases

Stichwörter der Autor:innen

Cutaneous neurofibromasMEK inhibitor binimetinibNeurofibromatosis type 1Nf1 mutant miceTumor Schwann cells

Substanzen

binimetinibBenzimidazolesProtein Kinase InhibitorsMitogen-Activated Protein Kinases

Autor:innen und Institutionen

  • Mondor Institute for Biomedical Research, Creteil, France.
  • Mondor Institute for Biomedical Research, Creteil, France; Dermatology Department, Centre de Référence des Neurofibromatoses, Hôpital Henri-Mondor, AP-HP, Créteil, France.
  • Pierre Fabre Dermatology, Toulouse, France.
  • Mondor Institute for Biomedical Research, Creteil, France. Electronic address: katarzyna.radomska@inserm.fr.
  • Mondor Institute for Biomedical Research, Creteil, France. Electronic address: piotr.topilko@inserm.fr.

Förderung

  • Johns Hopkins University
  • Les Laboratories Pierre Fabre
  • Neurofibromatosis Therapy Acceleration Program
  • Fondation Maladies Rares
  • Cancéropôle Ile de France

Zitieren

APA

Coulpier, F., Pulh, P., Oubrou, L., Naudet, J., Fertitta, L., Gregoire, J. M., Bocquet, A., Schmitt, A. M., Wolkenstein, P., Radomska, K. J., & Topilko, P. (2023). Topical delivery of mitogen-activated protein kinase inhibitor binimetinib prevents the development of cutaneous neurofibromas in neurofibromatosis type 1 mutant mice. Translational Research. https://doi.org/10.1016/j.trsl.2023.06.003

Vancouver

Coulpier F, Pulh P, Oubrou L, Naudet J, Fertitta L, Gregoire JM, et al. Topical delivery of mitogen-activated protein kinase inhibitor binimetinib prevents the development of cutaneous neurofibromas in neurofibromatosis type 1 mutant mice. Translational Research. 2023. doi:10.1016/j.trsl.2023.06.003

BibTeX
@article{Coulpier2023,
  author = {Coulpier, Fanny and Pulh, Pernelle and Oubrou, Layna and Naudet, Julie and Fertitta, Laura and Gregoire, Jean-Marc and Bocquet, Arnaud and Schmitt, Anne-Marie and Wolkenstein, Pierre and Radomska, Katarzyna J and Topilko, Piotr},
  title = {Topical delivery of mitogen-activated protein kinase inhibitor binimetinib prevents the development of cutaneous neurofibromas in neurofibromatosis type 1 mutant mice},
  journal = {Translational Research},
  year = {2023},
  doi = {10.1016/j.trsl.2023.06.003}
}
Kostenlos starten →